Updated
Eton PharmaceuticalsETON · Healthcare
$56.46+19.75%
Market cap$1.6B
IndustryDrug Manufacturers - Specialty & Generic

Eton Pharmaceuticals (ETON) Superinvestor holders

14 of the superinvestors we track hold Eton Pharmaceuticals (ETON) in their latest 13F filings, $88M in total.

Summary

The largest holder is Wilmot Harkey (Nantahala Capital Management), with $43M, 2.6% of the portfolio.

In their latest quarter: 4 opened a new position, 5 added, 3 trimmed.

Who holds it

Each investor's latest 13F filing, largest stake first. What a 13F shows.

InvestorLast changeSharesValue% of portfolioFiled for
Wilmot Harkey
Nantahala Capital Management
Held 1,175,951$43M 2.6%Q2 2026
Paul Marshall
Marshall Wace
Added 249,182$9M 0.0%Q2 2026
Wasatch
Wasatch Global Investors
Added 157,802$8M 0.1%Q3 2026
David Shaw
D. E. Shaw & Co.
New position 188,452$7M 0.0%Q2 2026
J. Carlo Cannell
Cannell Capital
Trimmed 170,747$6M 4.3%Q2 2026
Two Sigma
Two Sigma Investments
Added 116,291$4M 0.0%Q2 2026
Acadian
Acadian Asset Management
Added 75,468$4M 0.0%Q3 2026
Jim Simons
Renaissance Technologies
Trimmed 52,300$2M 0.0%Q2 2026
Dan Davidowitz
Polen Capital Management
Added 45,379$2M 0.0%Q2 2026
Steve Cohen
Point72 Asset Management
New position 44,918$2M 0.0%Q2 2026
Man Group
Man Group plc
New position 16,152$584,702 0.0%Q2 2026
Joel Greenblatt
Gotham Asset Management
New position 15,982$578,548 0.0%Q2 2026
Peter Muller
PDT Partners
Held 14,891$539,054 0.0%Q2 2026
Alan Howard
Brevan Howard
Trimmed 7,955$287,971 0.0%Q2 2026

Holders by quarter

QuarterSuperinvestors holding it
Q2 202614
Q1 20268
Q4 20258
Q3 20257
Q2 20258
Q1 20259
Q4 20247
Q3 20245

Questions about Eton Pharmaceuticals

Which superinvestors own Eton Pharmaceuticals?

14 of the superinvestors we track hold Eton Pharmaceuticals (ETON) in their latest 13F filings, $88M in total. Wilmot Harkey, Paul Marshall, Wasatch, David Shaw, J. Carlo Cannell, Two Sigma.

Who is the largest superinvestor holder of ETON?

The largest holder is Wilmot Harkey (Nantahala Capital Management), with $43M, 2.6% of the portfolio.

From Eton Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.

Investingly

Better research starts here.

Every filing, chart and insider trade behind Eton Pharmaceuticals and thousands of other companies, in one place. Free to start.